We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Blood Test Developed to Indicate Breast Cancer Risk

By LabMedica International staff writers
Posted on 10 Jul 2014
Print article
Image: Illumina’s Infinium Human Methylation BeadChip Kits (Photo Courtesy of University of Munster).
Image: Illumina’s Infinium Human Methylation BeadChip Kits (Photo Courtesy of University of Munster).
A simple blood test to help predict the likelihood of a woman developing breast cancer has been developed, as the idea that genetic mutations are the sole contributors to the development of the disease is changing.

Extensive genome-wide association studies have identified a number of single nucleotide polymorphisms (SNPs) associated with breast cancer risk whereas a gene mutation associated DNA methylation signature in blood cells could predict sporadic breast cancer incidence and survival.

Scientists at the University College London (UK) and their colleagues analyzed whole blood samples from two cohorts of breast cancer 1, early onset (BRCA1) gene mutation carriers and controls without a BRCA1 mutation. A total of 152 women, 75 cancer cases and 77 controls, were selected from those who provided both a peripheral blood and a buccal cell sample at the age of 53 in 1999, who had not previously developed any cancer.

The DNA from whole blood and tissues was extracted and DNA methylation analysis was performed using the validated Infinium Human Methylation BeadChip (Illumina; San Diego, CA, USA) or Illumina’s Infinium Human Methylation450 BeadChip kit. The methylation status of a specific CpG site, where a cytosine nucleotide occurs next to a guanine nucleotide, was calculated from the intensity of the methylated (M) and unmethylated (U) alleles, as the ratio of fluorescent signals.

The team analyzed DNA methylation (DNAme) of 27,578 CpGs in white blood cell (WBC) samples from a total of 72 women with a known BRCA1 mutation and 72 women with no mutation in the BRCA1 or BRCA2 gene. The scientists found that the women who developed both hereditary and non-hereditary breast cancer shared the same signature. The investigators believe that the epigenetic signature may be responsible for silencing genes in immune cells and if these genes are silenced, then the immune system may be less able to prevent the development of breast cancer.

Martin Widschwendter, MD, a professor of Gynecological Oncology and lead author of the study, said, “We identified an epigenetic signature in women with a mutated BRCA1 gene that was linked to increased cancer risk and lower survival rates. Surprisingly, we found the same signature in large cohorts of women without the BRCA1 mutation and it was able to predict breast cancer risk several years before diagnosis. The data is encouraging since it shows the potential of a blood-based epigenetic test to identify breast cancer risk in women without known predisposing genetic mutations.” The study was published on June 27, 2014, in the journal Genome Medicine.

Related Links:

University College London 
Illumina 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.